COVID-19 Vaccines and the Skin: The landscape of cutaneous vaccine reactions worldwide
Reads0
Chats0
TLDR
The authors reviewed the dermatologic manifestations of COVID-19 vaccines as reported in clinical trial data and summarized additional observational reports of skin reactions to COVID19 vaccines, concluding that early-onset local injection reactions were the most common cutaneous side effects observed in clinical trials, while delayed injection reactions reported outside of clinical trials.About:
This article is published in Dermatologic Clinics.The article was published on 2021-05-31 and is currently open access. It has received 75 citations till now.read more
Citations
More filters
Journal ArticleDOI
Cutaneous findings following COVID-19 vaccination: Review of world literature and own experience.
Thilo Gambichler,Stefanie Boms,Laura Susok,Heinrich Dickel,C. Finis,N. Abu Rached,M. Barras,Markus Stücker,Dimitri Kasakovski,Dimitri Kasakovski +9 more
TL;DR: There is growing evidence that not only the novel coronavirus disease (COVID-19) but also the COVID19 vaccines can cause a variety of skin reactions as mentioned in this paper, including delayed large local skin lesions, inflammatory reactions in dermal filler or previous radiation sites or even old BCG scars.
Journal ArticleDOI
Clinical and pathologic correlation of cutaneous COVID-19 vaccine reactions including V-REPP: A registry-based study
TL;DR: The most common histopathologic reaction pattern was spongiotic dermatitis, which clinically ranged from robust papules with overlying crust, to pityriasis rosea-like eruptions, to pink papule with fine scale as discussed by the authors .
Journal ArticleDOI
Clinical and Pathologic Correlation of Cutaneous COVID-19 Vaccine Reactions including V-REPP: A Registry Based Study.
Devon E. McMahon,Esther E. Freeman,Carrie L. Kovarik,William Damsky,Misha Rosenbach,Jules B. Lipoff,Anisha Tyagi,Grace Chamberlin,Ramie Fathy,Rosalynn M. Nazarian,Seemal R. Desai,Henry W. Lim,Bruce H. Thiers,George J. Hruza,Lars E. French,Lars E. French,Kimberly G. Blumenthal,Lindy P. Fox,Esther E. Freeman +18 more
TL;DR: In this article, the authors defined a subset of vaccine-related eruption of papules and plaques, as well as 12 other patterns, following COVID-19 vaccination and classified them by reaction patterns.
Journal ArticleDOI
Cutaneous Adverse Reactions to COVID-19 Vaccines: Insights from an Immuno-Dermatological Perspective.
Dennis Niebel,Natalija Novak,Jasmin Wilhelmi,Jana Ziob,Dagmar Wilsmann-Theis,Thomas Bieber,Joerg Wenzel,Christine Braegelmann +7 more
TL;DR: In this paper, the authors performed a literature research concerning cutaneous adverse drug reactions (ADRs) to different COVID-19 vaccines, and incorporated their own experiences, finding that injection site reactions are the most frequent side effects arising from all vaccine types.
Journal ArticleDOI
A systematic review on mucocutaneous presentations after COVID‐19 vaccination and expert recommendations about vaccination of important immune‐mediated dermatologic disorders
Farnoosh Seirafianpour,Homa Pourriyahi,M. Mesgarha,Arash Pour Mohammad,Zoha Shaka,Azadeh Goodarzi +5 more
TL;DR: Based on the findings, mucocutaneous adverse events were mostly non‐significant, self‐limiting reactions, and for the more uncommon moderate to severe reactions, guidelines and consensus position papers could be of great importance to provide those at higher risks and those with specific worries of flare‐ups or inefficient immunization with sufficient recommendations to safely schedule their vaccine doses, or avoid vaccination if they have the discussed contra‐indications.
References
More filters
Journal ArticleDOI
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.
Fernando P. Polack,Stephen J. Thomas,Nicholas Kitchin,Judith Absalon,Alejandra Gurtman,Stephen Lockhart,John L. Perez,Gonzalo Pérez Marc,Edson D. Moreira,Cristiano Zerbini,Ruth Bailey,Kena A. Swanson,Satrajit Roychoudhury,Kenneth Koury,Ping Li,Warren Kalina,David A. Cooper,Robert W. Frenck,Laura L. Hammitt,Özlem Türeci,Haylene Nell,Axel Schaefer,Serhat Ünal,Dina B. Tresnan,Susan Mather,Philip R. Dormitzer,Ugur Sahin,Kathrin U. Jansen,William C. Gruber +28 more
TL;DR: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older and safety over a median of 2 months was similar to that of other viral vaccines.
Journal ArticleDOI
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.
Merryn Voysey,Clemens Sac.,Shabir A. Madhi,Lily Yin Weckx,P M Folegatti,Parvinder K. Aley,Brian Angus,Vicky L. Baillie,Shaun Barnabas,Q E Bhorat,S Bibi,Carmen Briner,P Cicconi,Andrea M. Collins,R Colin-Jones,Clare L. Cutland,Thomas C. Darton,Keertan Dheda,Duncan Cja.,Emary Krw.,Katie J. Ewer,Lee Fairlie,Saul N. Faust,Shuo Feng,Daniela M. Ferreira,Adam Finn,Anna Goodman,Catherine M. Green,Christopher A Green,Paul T. Heath,Christopher Hill,Helen Hill,Ian Hirsch,Hodgson Shc.,Allen Izu,S Jackson,D Jenkin,Joe Ccd.,S Kerridge,Anthonet Koen,Gaurav Kwatra,Rajeka Lazarus,Alison M. Lawrie,A Lelliott,Vincenzo Libri,Patrick J. Lillie,R Mallory,Mendes Ava.,Eveline Pipolo Milan,Angela M. Minassian,Alastair McGregor,Hazel Morrison,Y Mujadidi,Amit J Nana,P J O’Reilly,S D Padayachee,A Pittella,E Plested,Katrina M Pollock,M N Ramasamy,S Rhead,Alexandre Vargas Schwarzbold,Nisha Singh,Andrew Smith,R Song,Matthew D. Snape,Eduardo Sprinz,Rebecca K. Sutherland,R Tarrant,E. Thomson,M E Török,Mark Toshner,Turner Dpj.,Johan Vekemans,Tonya Villafana,Watson Mee.,C J Williams,Alexander D. Douglas,Hill Avs.,Teresa Lambe,Sarah C. Gilbert,Andrew J. Pollard +81 more
TL;DR: ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials.
Journal ArticleDOI
Sex differences in immune responses
Sabra L. Klein,Katie L. Flanagan +1 more
TL;DR: It is emphasized that sex is a biological variable that should be considered in immunological studies and contribute to variations in the incidence of autoimmune diseases and malignancies, susceptibility to infectious diseases and responses to vaccines in males and females.
Journal ArticleDOI
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.
Lindsey R. Baden,Hana M. El Sahly,Brandon Essink,Karen L. Kotloff,Sharon E. Frey,Rick Novak,David Diemert,Stephen A. Spector,Nadine Rouphael,C. Buddy Creech,John W McGettigan,Shishir Khetan,Nathan Segall,Joel Solis,Adam Brosz,Carlos Fierro,Howard J. Schwartz,Kathleen M. Neuzil,Lawrence Corey,Peter B. Gilbert,Holly Janes,Dean Follmann,Mary A. Marovich,John R. Mascola,Laura Polakowski,Julie E. Ledgerwood,Barney S. Graham,Hamilton Bennett,Rolando Pajon,Conor Knightly,Brett Leav,Weiping Deng,Honghong Zhou,Shu Liang Han,Melanie Ivarsson,Jacqueline Miller,Tal Z Zaks +36 more
TL;DR: The mRNA-1273 vaccine as discussed by the authors is a lipid nanoparticle-encapsulated mRNA-based vaccine that encodes the prefusion stabilized full-length spike protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes Covid-19.
Journal ArticleDOI
Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia.
Denis Y. Logunov,Inna V. Dolzhikova,Dmitry V. Shcheblyakov,A. I. Tukhvatulin,Olga V. Zubkova,Alina S. Dzharullaeva,Anna V. Kovyrshina,Nadezhda L. Lubenets,Daria M. Grousova,Alina S. Erokhova,Andrei G. Botikov,Fatima M. Izhaeva,Olga Popova,Tatiana A Ozharovskaya,Ilias B Esmagambetov,Irina A Favorskaya,Denis I. Zrelkin,Daria V Voronina,Dmitry N. Shcherbinin,Alexander S. Semikhin,Yana V. Simakova,Elizaveta A. Tokarskaya,Daria A. Egorova,M M Shmarov,Natalia A. Nikitenko,Vladimir A. Gushchin,Elena A Smolyarchuk,Sergey Zyryanov,Sergei V. Borisevich,Boris S. Naroditsky,Alexander L. Gintsburg +30 more
TL;DR: Gam-COVID-Vac (Sputnik V) showed a good safety profile and induced strong humoral and cellular immune responses in participants in phase 1/2 clinical trials as discussed by the authors.